This early phase I trial evaluates the uptake of the imaging agent [68Ga]-pentixafor in patients with blood cancer or solid tumors who are undergoing positron emission tomography (PET)/computed tomography (CT). The uptake of [68Ga]-pentixafor is the amount of absorption of the agent into tissues and cells. A PET/CT scan shows how tissues and organs are functioning. [68Ga]-pentixafor is a radioactive tracer that is given through a vein, and it gives off a small amount of radioactivity as it travels throughout the body. The radioactivity builds up in the locations where disease is, and it can help PET/CT scans see and take pictures of the disease. This trial aims to see whether [68Ga]-pentixafor works better than standard of care fluorodeoxyglucose ([18F]-FDG) in detecting and providing information about blood cancers and solid tumors.
Additional locations may be listed on ClinicalTrials.gov for NCT05093335.
Locations matching your search criteria
United States
New York
New York
Memorial Sloan Kettering Cancer CenterStatus: Active
Contact: Anton Nosov
Phone: 212-639-8575
PRIMARY OBJECTIVE:
I. To obtain gallium Ga 68 pentixafor ([68Ga]-Pentixafor) biodistribution data in hematologic and solid tumor patients to establish a solid base for future experiments.
SECONDARY OBJECTIVES:
I. To determine whether [68Ga]-Pentixafor uptake differs between different blood cancers (e.g. different lymphoma subtypes) and solid tumors, and between involved versus (vs.) uninvolved bone marrow according to biopsy/histology.
II. To determine, by means of post-treatment [68Ga]-Pentixafor-PET performed in a subset of patients, possible effects of therapies on tracer biodistribution.
III. To perform safety monitoring using standard serious adverse event (SAE) reporting.
OUTLINE:
Patients receive gallium Ga 68 pentixafor intravenously (IV) and simultaneously undergo PET over 30 minutes. Starting 30-60 minutes post injection, patients undergo PET/CT or PET/magnetic resonance imaging (MRI) over 30 minutes. Some patients may receive gallium Ga 68 pentixafor and undergo PET/CT or PET/MRI scans twice, once before and once after standard of care treatment.
One day after completion of study intervention, patients receive a follow up phone call.
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorAnton Nosov
